ReviewWorld journal of gastroenterology2019
Update on hepatocellular carcinoma: Pathologists' review.
Review in World journal of gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 163 citations in OpenAlex.
- Clinical application of thioredoxin reductase as a novel biomarker in liver cancer.Scientific reports · 2021Trial
- Artificial intelligence in hepatocellular carcinoma: imaging-based subtyping and prediction of treatment response and prognosis.Abdominal radiology (New York) · 2026Review
- Artificial intelligence in hepatocellular carcinoma diagnosis and AI-assisted treatment support: Current landscape and future directions.Liver research (Beijing, China) · 2026Review
- Elevated TARDBP expression correlates with an unfavorable prognosis, immune evasion, and poor immune efficacy in hepatocellular carcinoma.Translational cancer research · 2026Article
- Multifocal hepatocellular carcinoma in a noncirrhotic liver: A diagnostic pitfall mimicking cholangiocarcinoma and metastatic disease.Radiology case reports · 2026Article
- GPD1L supports glycerol-3-phosphate and triacylglycerol synthesis and promotes tumor progression in HCC.Hepatology (Baltimore, Md.) · 2026Article
- Label-free multiphoton microscopy and machine learning for recognition of hepatocellular carcinoma.Scientific reports · 2026Article
- FOXK1 induced upregulation of KIF20A promotes hepatocellular carcinoma progression via Wnt/β-Catenin/EMT signaling.Cellular and molecular life sciences : CMLS · 2026Article
- Potential Indicators for the Development of Hepatocellular Carcinoma: A Diagnostic Strategy.Current topics in medicinal chemistry · 2026Review
- Revealing the prognostic potential of natural killer cell-related genes in hepatocellular carcinoma: the key role of NRAS.Discover oncology · 2025Article
- Clinicopathological Study on Morphological Subtypes of Hepatocellular Carcinoma: A Single Tertiary Referral Center Experience.Cancer reports (Hoboken, N.J.) · 2025Article
- Comprehensive Bioinformatic Analysis Reveals an Autophagy-related Gene Signature for Predicting Outcome, Immune Status, and Drug Sensitivity in Hepatocellular Carcinoma.Recent patents on anti-cancer drug discovery · 2025Article
- Multi-platform integration of histopathological images and omics data predicts molecular features and prognosis of hepatocellular carcinoma.Frontiers in oncology · 2025Article
- Pathomics signatures and cuproptosis-related genes signatures for prediction of prognosis in patients with hepatocellular carcinoma.Translational cancer research · 2024Article
- Review
- Patterns and Clinicopathological Features of Histologically Proven Metastases in Hepatocellular Carcinoma.Cureus · 2024Article
- Hedgehog components are overexpressed in a series of liver cancer cases.Scientific reports · 2024Article
- Electrochemotherapy with intravenous, intratumoral, or combined administration of bleomycin in the treatment of colorectal hepatic metastases in a rat model.Scientific reports · 2024Article
- Molecular Genealogy of Metabolic-associated Hepatocellular Carcinoma.Seminars in liver disease · 2024Review
- Developing risk models and subtypes of autophagy-associated LncRNAs for enhanced prognostic prediction and precision in therapeutic approaches for liver cancer patients.Oncology research · 2024Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Histopathologic diversity and several distinct histologic subtypes of hepatocellular carcinoma (HCC) are well-recognized. Recent advances in molecular pathology and growing knowledge about the biology associated with distinct histologic features and immuno-profile in HCC allowed pathologists to update classifications. Improving sub-classification will allow for more clinically relevant diagnoses and may allow for stratification into biologically meaningful subgroups. Therefore, immuno-histochemical and molecular testing are not only diagnostically useful, but also are being incorporated as crucial components in predicting prognosis of the patients with HCC. Possibilities of targeted therapy are being explored in HCC, and it will be important for pathologists to provide any data that may be valuable from a theranostic perspective. Herein, we review and provide updates regarding the pathologic sub-classification of HCC. Pathologic diagnostic approach and the role of biomarkers as prognosticators are reviewed. Further, the histopathology of four particular subtypes of HCC: Steatohepatitic, clear cell, fibrolamellar and scirrhous - and their clinical relevance, and the recent consensus on combined HCC-cholangiocarcinoma is summarized. Finally, emerging novel biomarkers and new approaches to HCC stratification are reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.